Chronic Mucocutaneous Candidiasis: Immunologic and Antibiotic Therapy

  1. CHARLES H. KIRKPATRICK, M.D.; and
  2. TERRILL K. SMITH
  1. Bethesda, Maryland

    Abstract

    Ten patients with chronic mucocutaneous candidiasis were studied immunologically and treated with either intravenous amphotericin B, transfer factor, or both of the agents. Five patients (late-onset cases) developed candidiasis after they were 5 years old, had less severe immunologic deficits, and responded to treatment with amphotericin B. Four of these patients have had remissions of 12 to 38 months, and in two patients negative, delayed candida skin tests became positive, suggesting recovery of immunologic function. The other five patients (early-onset cases) developed candidiasis during infancy or early childhood and had severe impairments of cellular immunity, often with complete anergy. Transfer factor from donors with positive skin tests caused conversion of delayed responses in these patients but did not produce beneficial or detrimental clinical effects. Two early-onset, anergic patients then received amphotericin and chronic transfer factor therapy; both have been free of cutaneous candidiasis for more than 2 years.

    Article and Author Information

    • ▸From the Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland.

    • ▸Requests for reprints should be addressed to Charles H. Kirkpatrick, M.D., Building 10, Room 11B-13, National Institutes of Health, Bethesda, Maryland 20014.

      • Received August 23, 1973.
      • Accepted November 30, 1973.
    « Previous | Next Article »Table of Contents